Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer

BACKGROUND: Nivolumab (NIVO) and irinotecan (IRI) are standard treatments for refractory advanced gastric cancer (AGC); however, it is unclear which drug should be administered first or in which cases. The tumor growth rate (TGR) during preceding treatment is reported to be associated with tumor res...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, K., Masuishi, T., Fushiki, K., Nakano, S., Kawamoto, Y., Narita, Y., Tsushima, T., Harada, K., Kadowaki, S., Todaka, A., Yuki, S., Tajika, M., Machida, N., Komatsu, Y., Yasui, H., Muro, K., Kawakami, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209093/
https://www.ncbi.nlm.nih.gov/pubmed/34119801
http://dx.doi.org/10.1016/j.esmoop.2021.100179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209093/
https://www.ncbi.nlm.nih.gov/pubmed/34119801
http://dx.doi.org/10.1016/j.esmoop.2021.100179

Ejemplares similares